The New Risk Map for Pharmaceutical Pricing

I was grateful to join Melanie Whittington, PhD on Perspectives by the Leerink Center for Pharmacoeconomics for a conversation about the U.S. Trade Representative’s Section 301 investigation into Germany’s pharmaceutical pricing and reimbursement practices. The interview can be found here.

The investigation itself is important, but I think the larger point is even more important.

The status quo is over.

Pharmaceutical companies and investors can no longer look at pricing, reimbursement, trade policy, launch planning, manufacturing, and patient access as separate issues. These areas are beginning to move together, especially for companies operating across the U.S., EU, and UK.

For a long time, pharmaceutical pricing was mostly treated as a domestic reimbursement issue. In the United States, that meant looking at Medicare, CMS, PBMs, commercial payers, the Inflation Reduction Act, and state-level access questions. In Europe, it meant looking country by country at health technology assessment, national budgets, reimbursement decisions, and launch sequencing.

Those issues still matter. They always will. The difference now is that trade policy is becoming part of the pricing conversation.

Section 301, Section 232, Most Favored Nation-style proposals, tariff discussions, and cross-border pricing arrangements are forcing companies to think differently about market strategy. A pricing decision in one country may no longer stay in that country. A reimbursement proposal in Europe may become part of a broader U.S. trade discussion. A launch strategy that once looked commercially sound may need to be reconsidered through a geopolitical and policy lens.

That is especially important because the EU is not a monolith. The European Union may operate as a commercial bloc in certain contexts, but pharmaceutical pricing and reimbursement remain deeply national. Germany, France, Italy, Spain, the Netherlands, and other countries each bring their own budget pressures, political expectations, health system priorities, and views of value.

That is why it is too simple to say that Europe is just about “price controls.” Pricing decisions are tied to clinical value, budget impact, insurance systems, patient access, politics, and long-term health system planning. Once trade policy enters that discussion, the risk map changes.

This matters for executives, boards, and investors. A company may have strong science, promising clinical data, and a compelling patient story. Those things are essential, but they are no longer enough on their own.

The company also has to explain where it will launch, how it expects to be reimbursed, what pricing assumptions support the business model, how those assumptions could change, and whether trade or policy pressure could affect the commercial plan. These questions matter even for biotech companies that are years away from commercialization because many of the assumptions about market size, pricing, access, manufacturing, and return on investment are made long before launch.

The patient access question cannot be separated from this either. If pricing and trade disputes create uncertainty, companies may delay launches, rethink markets, or narrow their commercial strategy. That can affect whether patients get access to innovative therapies, when they get access, and where that access happens first.

At the same time, policymakers are under pressure to make medicines more affordable and health systems more sustainable. That pressure is not going away.

That is why the next phase of pharmaceutical strategy requires a more connected view. Drug pricing is not only a reimbursement issue. Trade policy is not only a government relations issue. Market access is not only a commercial issue. Investor risk is not only a finance issue.

These issues now move together.

At Lanton Strategies International, we are watching these developments because they sit at the intersection of policy, reimbursement, trade, market access, and capital strategy across the U.S., EU, and UK.

For pharmaceutical companies, biotech executives, investors, and health-sector leaders, the question is not whether the rules are changing.

They are.

The work now is understanding what comes next.

When Drug Pricing Becomes a Trade Dispute

The United States has launched a Section 301 investigation into Germany over pharmaceutical pricing and reimbursement policies, with USTR characterizing the issue as “persistent underpayment for innovative pharmaceutical products.”

For multinational pharmaceutical and biotech companies operating across the Atlantic corridor, this is an important regulatory and market access signal.

The investigation appears tied to German healthcare cost-containment legislation that could further reduce spending on innovative medicines. While the trade process may take time to unfold, the larger issue is already clear: domestic healthcare pricing policy is now being viewed through a trade enforcement lens.

That matters because Germany is not just another European market. It is one of the most important pharmaceutical markets in Europe, and its reimbursement policies can influence launch sequencing, pricing strategy, and broader European market planning.

For life sciences companies, this creates a new layer of uncertainty. Pricing, reimbursement, intellectual property protection, market access, and trade enforcement are no longer separate conversations. They are becoming part of the same commercial risk analysis.

The investigation also reflects a broader U.S. policy argument: American patients and companies should not carry a disproportionate share of the global cost of pharmaceutical research and development while other wealthy markets use aggressive reimbursement controls to limit spending.

This does not mean tariffs are inevitable. USTR has suggested that the issue could potentially be resolved through negotiations, including a path that expands access to innovative medicines while ensuring fair reimbursement for pharmaceuticals made by American workers. Still, the use of Section 301 against Germany is significant because it shows how quickly pricing policy can become a trade dispute.

For pharmaceutical and biotech companies, the takeaway is clear. Market-entry strategy cannot focus only on regulatory approval or clinical value. It also has to account for how governments use pricing rules, budget controls, and trade tools to shape the value of innovation.

This is exactly the type of geopolitical and market access risk we track closely at Lanton Strategies International. As pricing policy and international trade enforcement continue to intersect, companies will need to think more carefully about where they launch, how they price, and how policy risk affects long-term commercial planning.

Beyond the Deal Activity: Strategic Questions Emerging from Global Pharmaceutical R&D

A recent Pharmaceutical Executive article seen here examined China's growing role in pharmaceutical R&D and licensing activity. I was pleased to contribute to that discussion, which highlights an important trend shaping the future of healthcare and life sciences.

The growth in cross-border pharmaceutical partnerships reflects a broader reality: innovation is becoming increasingly global. Scientific talent, clinical development capabilities, manufacturing capacity, and investment opportunities are no longer concentrated in a single market. Pharmaceutical companies are evaluating opportunities wherever they believe innovation can be developed efficiently and brought to patients successfully.

While much attention is understandably focused on the volume of deal activity, the more interesting questions may lie beneath the transactions themselves.

Healthcare executives and investors are increasingly evaluating factors that extend beyond the science. Reimbursement environments, market access pathways, trade policy, industrial strategy, supply chain resilience, and geopolitical developments are all becoming part of the strategic conversation.

The challenge is that scientific innovation and commercial success do not always follow the same path.

A promising therapy may emerge from one market, attract investment from another, undergo clinical development across multiple regions, and ultimately depend on regulatory approvals, reimbursement decisions, and commercialization strategies in entirely different jurisdictions. The path from discovery to patient access is becoming more interconnected and, in many cases, more complex.

For healthcare and life sciences leaders, this raises several important questions.

How should companies evaluate policy risk alongside scientific opportunity?

How should investors think about reimbursement uncertainty when assessing long-term value?

How should organizations balance global sourcing of innovation with evolving national priorities related to healthcare security, industrial policy, and supply chain resilience?

These questions do not diminish the importance of scientific innovation. Rather, they recognize that innovation alone is not always sufficient to determine market success.

As pharmaceutical development becomes more global, the healthcare organizations that succeed may be those that understand both the science and the broader strategic environment in which that science operates.

The Pharmaceutical Executive article is a valuable contribution to this discussion and highlights an important development that healthcare leaders should continue to watch closely. The implications extend well beyond individual transactions and point toward a healthcare market that is becoming increasingly interconnected across innovation, policy, capital, and commercialization.

When Regulatory Signals Reshape Valuation

For decades, the expectation that most new drugs would be supported by two adequate and well-controlled clinical trials operated as a structural assumption in the US regulatory system. It wasn’t simply a procedural norm. It became embedded in how companies planned development timelines, how investors modeled risk, and how boards evaluated capital allocation. Even when flexibility existed in practice, the baseline expectation created predictability. Predictability supports valuation.

When longstanding evidentiary expectations begin to evolve, even in subtle ways, the implications extend far beyond regulatory interpretation. They move directly into capital strategy.

At first glance, reconsidering the traditional two-trial expectation sounds technical. It feels like something that belongs in a regulatory affairs update or a clinical development memo. But step back. If the evidentiary framework shifts, development timelines may compress. If timelines compress, capital burn assumptions change. If capital burn assumptions change, fundraising strategy changes. When fundraising strategy changes, valuation follows.

That is not compliance. That is capital architecture.

The two trial expectation functioned as a stabilizing reference point. Sponsors understood the evidentiary threshold. Investors priced in the development pathway. Analysts anchored risk models to a familiar structure. When that baseline assumption begins to move, even in the direction of greater flexibility, discretion expands. Expanded discretion introduces both opportunity and variability.

Acceleration can increase capital efficiency. Variability can increase perceived risk.

Markets react to both.

Flexibility does not mean deregulation. The FDA’s mandate to ensure safety and efficacy remains central. The way evidentiary standards are interpreted, along with the circumstances under which alternative evidence may be considered sufficient, directly influences capital confidence. Regulatory posture now enters financial forecasting earlier in the lifecycle. It no longer waits for final approval to shape valuation assumptions.

For early-stage biotech firms, this can alter milestone sequencing and investor communication strategy. For later-stage sponsors, it may influence launch timing, commercialization planning, and capital deployment decisions. For institutional investors, it introduces a recalibration moment: how durable are existing risk assumptions if the evidentiary baseline becomes more fluid?

This development also carries transatlantic implications. For European life sciences companies seeking US market entry, the FDA approval pathway often anchors global strategy. If US evidentiary flexibility increases, development sequencing between the FDA and EMA may shift. Capital raises tied to anticipated regulatory inflection points may need re-modeling. Investor appetite across jurisdictions may adjust in response to perceived regulatory momentum.

Regulatory posture in Washington increasingly shapes boardroom discussions in Amsterdam, Berlin, and London.

The larger point is not about one evidentiary standard. It is about what happens when foundational assumptions begin to move. Healthcare regulation has always shaped market behavior. What is different now is the speed with which policy signals enter valuation models. Investors respond to direction as much as finality. Executive teams adjust capital strategy in response to posture, not just published guidance.

When the baseline shifts, financial models must shift with it.

The reconsideration of longstanding evidentiary expectations illustrates a broader structural trend: policy is no longer confined to compliance architecture. It has become capital infrastructure.

Those who recognize that early are better positioned to scale.